Last reviewed · How we verify
pemetrexed plus cisplatin
pemetrexed plus cisplatin is a Small molecule drug developed by Chinese Academy of Medical Sciences. It is currently FDA-approved. Also known as: Alimta.
At a glance
| Generic name | pemetrexed plus cisplatin |
|---|---|
| Also known as | Alimta |
| Sponsor | Chinese Academy of Medical Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (PHASE2)
- Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (PHASE1, PHASE2)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma (PHASE1, PHASE2)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC (PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pemetrexed plus cisplatin CI brief — competitive landscape report
- pemetrexed plus cisplatin updates RSS · CI watch RSS
- Chinese Academy of Medical Sciences portfolio CI
Frequently asked questions about pemetrexed plus cisplatin
What is pemetrexed plus cisplatin?
pemetrexed plus cisplatin is a Small molecule drug developed by Chinese Academy of Medical Sciences.
Who makes pemetrexed plus cisplatin?
pemetrexed plus cisplatin is developed and marketed by Chinese Academy of Medical Sciences (see full Chinese Academy of Medical Sciences pipeline at /company/chinese-academy-of-medical-sciences).
Is pemetrexed plus cisplatin also known as anything else?
pemetrexed plus cisplatin is also known as Alimta.
What development phase is pemetrexed plus cisplatin in?
pemetrexed plus cisplatin is FDA-approved (marketed).
Related
- Manufacturer: Chinese Academy of Medical Sciences — full pipeline
- Also known as: Alimta
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing